Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.

ABSTRACT:

Background

To support public health measures during the COVID-19 pandemic, oral opioid agonist treatment (OAT) take-home doses were expanded in Western countries with positive results. Injectable OAT (iOAT) take-home doses were previously not an eligible option, and were made available for the first time in several sites to align with public health measures. Building upon these temporary risk-mitigating guidelines, a clinic in Vancouver, BC continued to offer two of a possible three daily doses of take-home injectable medications to eligible clients. The present study explores the processes through which take-home iOAT doses impacted clients' quality of life and continuity of care in real-life settings.

Methods

Three rounds of semi-structured qualitative interviews were cond

SUBMITTER: Oviedo-Joekes E 

PROVIDER: S-EPMC10215060 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature